Newsroom
Sorted by: Latest
-
AM Best Afirma Ratings de Crédito da Liberty Mutual Surety Brasil Seguros S.A.
CIDADE DO MÉXICO--(BUSINESS WIRE)--AM Best afirmou o Financial Strength Rating A- (Excelente) e o Rating de Crédito de Emissor de Longo Prazo "a-" (Excelente) da Liberty Mutual Surety Brasil Seguros S.A. (LMSB) (São Paulo, Brasil). A perspectiva desses Ratings de Crédito (ratings) é estável. Os ratings refletem a solidez do balanço patrimonial da LMSB, que a AM Best avalia como forte, bem como seu desempenho operacional adequado, perfil empresarial limitado e gestão de risco da empresa (ERM) ap...
-
Activision Blizzard 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Activision Blizzard Inc. - ATVI
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 30, 2026 to file lead plaintiff applications in a securities class action lawsuit against Activision Blizzard Inc. (“Activision” or the "Company") (NasdaqGM: ATVI), if they sold Activision common stock between January 18, 2022 and October 13, 2023, inclusive (the “Class Period”) (excluding those tha...
-
GameStop Provides Fiscal Year 2026 Outlook
GRAPEVINE, Texas--(BUSINESS WIRE)--GameStop Corp. (NYSE: GME) (“GameStop” or the “Company”) today announced that, for the fiscal year ending January 30, 2027 ("fiscal year 2026"), the Company currently expects to generate Adjusted EBITDA in excess of $600 million, compared to Adjusted EBITDA of $345.4 million in fiscal year 2025. GameStop's leadership team remains focused on advancing the proposed acquisition of eBay, Inc. ("eBay"). Additional materials regarding the proposed transaction are fo...
-
Incyte gibt positive Stellungnahme des CHMP zu Opzelura ® (Ruxolitinib)-Creme zur Behandlung von Erwachsenen mit mittelschwerer atopischer Dermatitis bekannt
MORGES, Schweiz--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) gab heute bekannt, dass der Ausschuss für Humanarzneimittel (CHMP) der Europäischen Arzneimittelagentur (EMA) eine positive Stellungnahme abgegeben und die Zulassung von Opzelura® (Ruxolitinib)-Creme zur Behandlung von mittelschwerer atopischer Dermatitis (AD) bei erwachsenen Patienten, bei denen topische Kortikosteroide (TCS) und topische Calcineurin-Hemmer (TCI) unzureichend oder ungeeignet sind, empfohlen hat. „AD ist eine chronische Ha...
-
Samenvatting: Incyte kondigt positief CHMP-advies aan voor Opzelura® (ruxolitinib)-crème voor de behandeling van volwassenen met matige atopische dermatitis
MORGES, Zwitserland--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) heeft vandaag bekendgemaakt dat het Comité voor geneesmiddelen voor menselijk gebruik (CHMP) van het Europees Geneesmiddelenbureau (EMA) een positief advies heeft uitgebracht waarin wordt aanbevolen Opzelura® (ruxolitinib)-crème goed te keuren voor de behandeling van matige atopische dermatitis (AD) bij volwassen patiënten voor wie lokale corticosteroïden (TCS) en lokale calcineurineremmers (TCI) onvoldoende effectief of niet geschikt...
-
Riassunto: Incyte annuncia l'opinione positiva del CHMP per Opzelura® (ruxolitinib) crema per il trattamento della dermatite atopica moderata in pazienti adulti
MORGES, Svizzera--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) oggi ha annunciato che il Comitato per i prodotti medicinali per uso umano (CHMP) dell'Agenzia Europea per i Medicinali (EMA) ha espresso un'opinione positiva sul farmaco, raccomandando l'approvazione di Opzelura® (ruxolitinib) crema per il trattamento della dermatite atopica (DA) moderata in pazienti adulti per i quali i corticosteroidi topici (TCS) e gli inibitori topici della calcineurina (TCI) sono inadeguati o inadatti. Il testo orig...
-
Resumen: Incyte anuncia un dictamen favorable del CHMP sobre la crema Opzelura® (ruxolitinib) para tratar a los pacientes adultos con dermatitis atópica moderada
MORGES, Suiza--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) ha anunciado hoy que el Comité de Medicamentos de Uso Humano (Committee for Medicinal Products for Human Use, CHMP) de la Agencia Europea de Medicamentos (EMA) ha emitido un dictamen favorable en el que recomienda la autorización de la crema Opzelura® (ruxolitinib) para tratar la dermatitis atópica (DA) moderada en los pacientes adultos para quienes los corticosteroides tópicos (CT) y los inhibidores tópicos de la calcineurina (ITC) resultan...
-
KBRA Comments on Colony Bancorp, Inc.'s Proposed Merger with First Reliance Bancshares, Inc.
NEW YORK--(BUSINESS WIRE)--On June 24, 2026, Fitzgerald, GA-based Colony Bancorp, Inc. (NYSE: CBAN) (“Colony”), parent company of Colony Bank, and Florence, SC-based First Reliance Bancshares, Inc. (OTCQX: FSRL) (“First Reliance”), parent company of First Reliance Bank, jointly announced that they had entered into a definitive merger agreement pursuant to which First Reliance Bancshares, Inc. would merger with and into Colony Bancorp, Inc., and First Reliance Bank would merger with and into Col...
-
Tractor Supply and 4-H Collaborate With Starlink to Bridge the Digital Divide in Rural Communities
BRENTWOOD, Tenn.--(BUSINESS WIRE)--Tractor Supply Company (NASDAQ: TSCO), the largest rural lifestyle retailer in the United States; Starlink, the world’s most advanced satellite constellation that delivers reliable broadband connectivity nationwide, including to locations where high-speed internet has traditionally been too expensive, unreliable or entirely unavailable; and 4-H, America’s largest youth development organization, announced today an alliance aimed at expanding broadband access in...
-
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software
ATLANTA--(BUSINESS WIRE)--VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where...